NASDAQ:ABEO Abeona Therapeutics (ABEO) Stock Price, News & Analysis $5.10 +0.07 (+1.39%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.03▼$5.2550-Day Range$4.06▼$5.5152-Week Range$2.83▼$9.01Volume241,065 shsAverage Volume522,426 shsMarket Capitalization$208.90 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Abeona Therapeutics alerts: Email Address Abeona Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside272.5% Upside$19.00 Price TargetShort InterestHealthy7.95% of Float Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment1.10Based on 3 Articles This WeekInsider TradingAcquiring Shares$51,810 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.81) to ($1.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.52 out of 5 starsMedical Sector104th out of 936 stocksPharmaceutical Preparations Industry38th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAbeona Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAbeona Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Abeona Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.95% of the float of Abeona Therapeutics has been sold short.Short Interest Ratio / Days to CoverAbeona Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Abeona Therapeutics has recently decreased by 8.33%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAbeona Therapeutics does not currently pay a dividend.Dividend GrowthAbeona Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAbeona Therapeutics has received a 69.10% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases ", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Abeona Therapeutics is -1.03. Previous Next 2.8 News and Social Media Coverage News SentimentAbeona Therapeutics has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Abeona Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for ABEO on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Abeona Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $51,810.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of Abeona Therapeutics is held by insiders.Percentage Held by Institutions80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abeona Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Abeona Therapeutics are expected to grow in the coming year, from ($1.81) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abeona Therapeutics is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Abeona Therapeutics is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbeona Therapeutics has a P/B Ratio of 8.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Abeona Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Abeona Therapeutics Stock (NASDAQ:ABEO)Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Read More ABEO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABEO Stock News HeadlinesJuly 21, 2024 | finance.yahoo.comInstitutional investors own a significant stake of 39% in Abeona Therapeutics Inc. (NASDAQ:ABEO)July 11, 2024 | globenewswire.comAbeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology IndicationsJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 8, 2024 | globenewswire.comAbeona Therapeutics to Present at the Stifel Virtual Cell Therapy ForumJune 7, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEOJune 5, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEOJune 3, 2024 | globenewswire.comAbeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 30, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEOJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 28, 2024 | msn.comABEO: BLA Resubmission in 2H24May 28, 2024 | globenewswire.comAbeona Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 23, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEOMay 22, 2024 | uk.investing.comAbeona Therapeutics director buys $51,798 in company stockMay 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEOMay 16, 2024 | finance.yahoo.comQ1 2024 Abeona Therapeutics Inc Earnings CallMay 16, 2024 | finance.yahoo.comAbeona Therapeutics Inc (ABEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...May 15, 2024 | washingtonpost.comAbeona Therapeutics: Q1 Earnings SnapshotMay 15, 2024 | investorplace.comABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q1 2024See More Headlines Receive ABEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ABEO Previous SymbolOTCMKTS:ACCP CUSIPN/A CIK318306 Webwww.abeonatherapeutics.com Phone214-665-9495Fax214-905-5101EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$21.00 Low Stock Price Target$15.00 Potential Upside/Downside+272.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,190,000.00 Net MarginsN/A Pretax Margin-2,190.26% Return on Equity-543.60% Return on Assets-78.51% Debt Debt-to-Equity RatioN/A Current Ratio5.61 Quick Ratio5.61 Sales & Book Value Annual Sales$3.50 million Price / Sales59.68 Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book8.50Miscellaneous Outstanding Shares40,960,000Free Float38,792,000Market Cap$208.90 million OptionableOptionable Beta1.59 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Steven H. Rouhandeh (Age 61)Exec. Chairman Dr. Timothy J. Miller (Age 46)Pres, Chief Scientific Officer & Director Mr. Jeffrey Blaine Davis (Age 55)Chief Operating Officer Mr. Carsten Thiel (Age 54)Chief Exec. Officer Mr. Stephen B. Thompson (Age 64)Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer Key CompetitorsAclaris TherapeuticsNASDAQ:ACRSEquilliumNASDAQ:EQuniQureNASDAQ:QUREAcelRx PharmaceuticalsNASDAQ:ACRXLumos PharmaNASDAQ:LUMOView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 2,434 shares on 7/26/2024Ownership: 0.297%Rosalind Advisors Inc.Bought 1,750,000 shares on 7/12/2024Ownership: 4.272%Western Standard LLCBought 553,377 shares on 5/17/2024Ownership: 4.978%Leila AllandBought 11,000 shares on 5/16/2024Total: $51,810.00 ($4.71/share)Acadian Asset Management LLCBought 12,634 shares on 5/10/2024Ownership: 0.046%View All Insider TransactionsView All Institutional Transactions ABEO Stock Analysis - Frequently Asked Questions How have ABEO shares performed this year? Abeona Therapeutics' stock was trading at $5.01 at the start of the year. Since then, ABEO stock has increased by 1.8% and is now trading at $5.10. View the best growth stocks for 2024 here. How were Abeona Therapeutics' earnings last quarter? Abeona Therapeutics Inc (NASDAQ:ABEO) posted its quarterly earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.06. When did Abeona Therapeutics' stock split? Abeona Therapeutics shares reverse split on Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Abeona Therapeutics' major shareholders? Top institutional shareholders of Abeona Therapeutics include Rosalind Advisors Inc. (4.27%), Bank of New York Mellon Corp (0.30%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Vishwas Seshadri, Brendan M O'malley, Michael Amoroso, Christine Berni Silverstein, Faith L Charles, Mark Alvino, Todd Wider and Edward Carr. View institutional ownership trends. How do I buy shares of Abeona Therapeutics? Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Abeona Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Abeona Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Energy Transfer (ET), Sorrento Therapeutics (SRNE) and Micron Technology (MU). This page (NASDAQ:ABEO) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
